-
1دورية أكاديمية
المؤلفون: Maurice Sopacua, Carla M.L. Gorissen-Brouwers, Bianca T.A. de Greef, Isis B.T. Joosten, Catharina G. Faber, Ingemar S.J. Merkies, Janneke G.J. Hoeijmakers
المصدر: Clinical Neurophysiology Practice, Vol 7, Iss , Pp 115-119 (2022)
مصطلحات موضوعية: 5-point scale, Digit wrinkle scan, Small fiber neuropathy, Autonomic function, Digit vasoconstriction, Inter-observer reliability, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
الوصف: Objective: Stimulated skin wrinkling test (SSW) has been launched as a non-invasive diagnostic procedure. However, no normative age dependent values have been reported that can be applied in clinical practice. The objectives of the study were to (1) collect age-dependent normative values according to the 5-point scale assessment for the SSW, to (2) determine reliability scores for the obtained norm values, and to (3) introduce a new digital method for SSW assessment, the Digit Wrinkle Scan© (DWS©) for detection of wrinkles in a more quantitative manner. Methods: Firstly, 82 healthy participants were included, divided in 5 age groups. The participants underwent SSW using lidocaine and prilocaine topical cream. Secondly, 35 healthy participants were included to test whether the DWS© could be a novel manner to assess the grade of wrinkling quantitatively. We determined the inter-observer reliability of both methods. Also, the intra-observer reliability was calculated for the DWS©. Results: We found a decrease in normative values over age. The inter-observer reliability of assessment by the 5-point scale method was moderate after SSW (Cohen’s k: 0.53). Results of the DWS© indicate that total wrinkle length per mm2 showed moderate to good agreement for the 4th and 5th digits after SSW, and a low agreement for the other digits. Conclusions: Age-dependent normative values were obtained according to the 5-point scale, but its clinical application is doubtful since we found a moderate inter-observer reliability. We introduced the DWS© as a possible new method in order to quantify the grade of wrinkling. Significance: We found unsatisfactory reliability scores, which hampers its usefulness for clinical practice.
وصف الملف: electronic resource
العلاقة: http://www.sciencedirect.com/science/article/pii/S2467981X22000166Test; https://doaj.org/toc/2467-981XTest
-
2
المصدر: Current Opinion in Neurology. 35(5):545-552
مصطلحات موضوعية: Neurology, Neurology (clinical)
الوصف: PURPOSE OF REVIEW: Several conditions have been associated with the development of small fiber neuropathy (SFN). The list of metabolic, immune-mediated, infectious, toxic, drugs-related, and hereditary conditions is still growing and various hypotheses are made about the underlying pathophysiological mechanisms. Understanding these processes is important to provide new targets for treatment. In addition, the specific SFN phenotype can provide direction for the underlying etiology. This review discusses the latest developments concerning the expanding etiologies in SFN. RECENT FINDINGS: In the past 18 months, special attention has been paid to immunological etiologies, partly due to the coronavirus disease 2019 pandemic, but also new auto-antibodies in SFN have been demonstrated. Identifying patients with immune-mediated SFN can be challenging, since contrary to the classical distal sensory phenotype, a nonlength-dependent pattern is more common.Besides the etiologies of classical SFN, small fiber pathology is increasingly described in diseases without the typical neuropathic pain features of SFN, sometimes called syndromic SFN. However, the clinical relevance is not yet fully understood. SUMMARY: The expansion of the etiologies of SFN continues and brings more insight in possible targets for treatment. The clinical presentation may vary as a result of the underlying condition.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c17e782e08070680a7c582cc1260560Test
https://doi.org/10.1097/wco.0000000000001103Test -
3
المؤلفون: Christa Walgaard, Bart C Jacobs, Hester F Lingsma, Ewout W Steyerberg, Bianca van den Berg, Alexandra Y Doets, Sonja E Leonhard, Christine Verboon, Ruth Huizinga, Judith Drenthen, Samuel Arends, Ilona Kleine Budde, Ruud P Kleyweg, Krista Kuitwaard, Marjon F G van der Meulen, Johnny P A Samijn, Frederique H Vermeij, Jan B M Kuks, Gert W van Dijk, Paul W Wirtz, Filip Eftimov, Anneke J van der Kooi, Marcel P J Garssen, Cees J Gijsbers, Maarten C de Rijk, Leo H Visser, Roderik J Blom, Wim H J P Linssen, Elly L van der Kooi, Jan J G M Verschuuren, Rinske van Koningsveld, Rita J G Dieks, H Job Gilhuis, Korné Jellema, Taco C van der Ree, Henriette M E Bienfait, Catharina G Faber, Harry Lovenich, Baziel G M van Engelen, Rutger J Groen, Ingemar S J Merkies, Bob W van Oosten, W Ludo van der Pol, Willem D M van der Meulen, Umesh A Badrising, Martijn Stevens, Albert-Jan J Breukelman, Casper P Zwetsloot, Maaike M van der Graaff, Marielle Wohlgemuth, Richard A C Hughes, David R Cornblath, Pieter A van Doorn, Bart C. Jacobs, Hester F. Lingsma, Ewout W. Steyerberg, Bianca Van den Berg, Alexandra Y. Doets, Sonja E. Leonhard, Ruud P. Kleyweg, Marjon F.G. Van der Meulen, Johnny P.A. Samijn, Frederique H. Vermeij, Jan B.M. Kuks, Gert W. Van Dijk, Paul W. Wirtz, Anneke J. Van der Kooi, Marcel P.J. Garssen, Cees J. Gijsbers, Maarten C. De Rijk, Leo H. Visser, Roderik J. Blom, Wim H.J.P. Linssen, Elly L. Van der Kooi, Jan J.G.M. Verschuuren, Rinske Van Koningsveld, Rita J.G. Dieks, H. Job Gilhuis, Taco C. Van der Ree, Henriette M.E. Bienfait, Karin G. Faber, Baziel G.M. Van Engelen, Rutger J. Groen, Ingemar S.J. Merkies, Bob W. Van Oosten, W. Ludo Van der Pol, Willem D.M. Van der Meulen, Umesh A. Badrising, Albert-Jan J. Breukelman, Casper P. Zwetsloot, Maaike M. Van der Graaff, Richard A.C. Hughes, David R. Cornblath, Pieter A. Van Doorn, R.B. Althingh van Geusau, C.J.M. Van Boheemen, I.M. Bronner, B. Feenstra, C. Fokke, T.A. Hoogendoorn, R. Van Houten, A. Hovestad, P.J.H.W. Jansen, E. Keuter, J. Krudde, F.H.H. Linn, J. Lion, S.M. Manschot, S.J. Mellema, D.S.M. Molenaar, D.J. Nieuwkamp, D.G. Oenema, J.C.H. Van Oostrom, N.P. Van Orshoven, R.J.O. Van der Ploeg, S. Polman, A. Ruitenberg, L. Ruts, A.J.G.M. Schyns-Soeterboek, R. Trip
المساهمون: Neurology, Amsterdam Neuroscience - Neuroinfection & -inflammation, Immunology, Public Health, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), ANS - Neuroinfection & -inflammation, EURO-NMD
المصدر: The Lancet Neurology, 20(4), 275-283. Lancet Publishing Group
Walgaard, C, Jacobs, B C, Lingsma, H F, Steyerberg, E W, van den Berg, B, Doets, A Y, Leonhard, S E, Verboon, C, Huizinga, R, Drenthen, J, Arends, S, Budde, I K, Kleyweg, R P, Kuitwaard, K, van der Meulen, M F G, Samijn, J P A, Vermeij, F H, Kuks, J B M, van Dijk, G W, Wirtz, P W, Eftimov, F, van der Kooi, A J, Garssen, M P J, Gijsbers, C J, de Rijk, M C, Visser, L H, Blom, R J, Linssen, W H J P, van der Kooi, E L, Verschuuren, J J G M, van Koningsveld, R, Dieks, R J G, Gilhuis, H J, Jellema, K, van der Ree, T C, Bienfait, H M E, Faber, C G, Lovenich, H, van Engelen, B G M, Groen, R J, Merkies, I S J, van Oosten, B W, van der Pol, W L, van der Meulen, W D M, Badrising, U A, Stevens, M, Breukelman, A-J J, Zwetsloot, C P, van der Graaff, M M, Wohlgemuth, M, Hughes, R A C, Cornblath, D R, van Doorn, P A, Jacobs, B C, Lingsma, H F, Steyerberg, E W, Doets, A Y, Leonhard, S E, Kleine Budde, I, Kleyweg, R P, van der Meulen, M F G, Samijn, J P A, Vermeij, F H, Kuks, J B M, van Dijk, G W, Wirtz, P W, van der Kooi, A J, Garssen, M P J, Gijsbers, C J, de Rijk, M C, Visser, L H, Blom, R J, Linssen, W H J P, van der Kooi, E L, Verschuuren, J J G M, Dieks, R J G, Gilhuis, H J, van der Ree, T C, Bienfait, H M E, Faber, K G, van Engelen, B G M, Groen, R J, Merkies, I S J, van Oosten, B W, van der Pol, W L, van der Meulen, W D M, Badrising, U A, Breukelman, A-J J, Zwetsloot, C P, van der Graaff, M M, Hughes, R A C, Cornblath, D R, van Doorn, P A, Althingh van Geusau, R B, van Boheemen, C J M, Bronner, I M, Feenstra, B, Fokke, C, Hoogendoorn, T A, van Houten, R, Hovestad, A, Jansen, P J H W, Keuter, E, Krudde, J, Linn, F H H, Lion, J, Manschot, S M, Mellema, S J, Molenaar, D S M, Nieuwkamp, D J, Oenema, D G, van Oostrom, J C H, van Orshoven, N P, van der Ploeg, R J O, Polman, S, Ruitenberg, A, Ruts, L, Schyns-Soeterboek, A J G M, Trip, R & Dutch GBS Study Group 2021, ' Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial ', The Lancet Neurology, vol. 20, no. 4, pp. 275-283 . https://doi.org/10.1016/S1474-4422Test(20)30494-4
The Lancet Neurology, 20(4), 275-283. ELSEVIER SCIENCE INC
Lancet Neurology, 20(4), 275-283. ELSEVIER SCIENCE INC
Lancet Neurology, 20(4), 275-283. Elsevier Science
Lancet Neurology, 20, 275-283
Lancet neurology, 20(4), 275-283. Lancet Publishing Group
Lancet Neurology, 20, 4, pp. 275-283مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Placebo-controlled study, Placebo, Guillain-Barre Syndrome, law.invention, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, In patient, 030212 general & internal medicine, Adverse effect, Aged, Netherlands, biology, Guillain-Barre syndrome, business.industry, Immunoglobulins, Intravenous, Odds ratio, Middle Aged, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], medicine.disease, Prognosis, Treatment Outcome, biology.protein, Female, Neurology (clinical), Antibody, business, 030217 neurology & neurosurgery
الوصف: Summary Background Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barre syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barre syndrome with a predicted poor outcome. Methods In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (≥12 years) with Guillain-Barre syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of ≥6) according to the modified Erasmus Guillain-Barre syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7–9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barre syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. This study is registered with the Netherlands Trial Register, NTR 2224/NL2107. Findings Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barre syndrome disability score at 4 weeks was 1·4 (95% CI 0·6–3·3; p=0·45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13–24 weeks after randomisation). Interpretation Our study does not provide evidence that patients with Guillain-Barre syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other immune modulators in patients severely affected by Guillain-Barre syndrome. Funding Prinses Beatrix Spierfonds and Sanquin Plasma Products.
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac234079bfe0a75e9f04cbd3f24fe28Test
https://research.vumc.nl/en/publications/ed0fb2cb-ebfd-4d51-a9f8-133541aa7cfaTest -
4
المؤلفون: Fausto Adami, Jean-Christophe Antoine, Katie Beadon, Chiara Briani, Marta Campagnolo, Pieter A. van Doorn, Mathilde Duchesne, P. James B. Dyck, H. Stephan Goedee, Jean-Marc Léger, Federica Lessi, Marco Luigetti, Laurent Magy, Stéphane Mathis, Ingemar S.J. Merkies, Nicolette C. Notermans, Anne Louise Oaklander, Mariëlle H.J. Pruppers, Yusuf A. Rajabally, Pariwat Thaisetthawatkul, Jean-Michel Vallat
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1663fdcf8235efa3ec770974f4f3bdb6Test
https://doi.org/10.1016/b978-0-12-814572-2.09992-1Test -
5
المؤلفون: Filip Eftimov, Carina Bunschoten, Yusuf Rajabally, Luis Querol, Max E. Adrichem, Jeffrey Allen, Jean-Cristophe Antoine, Ivana Basta, Peter Van den Bergh, Patricia Blomkwist-Markens, Alexandra Breukel, David Cornblath, Kathrin Doppler, Stephan Goedee, Robert Hadden, Thomas Harbo, Fu Liong Hiew, Bart C. Jacobs, Helmar Lehmann, Michael P. Lunn, Ingemar S.J. Merkies, Eduardo Nobile-Orazio, Stephen Reddel, Jean-Michel Vallat, Antonino Uncini
المصدر: Neuromuscular Disorders. 28:178-184
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, business.industry, International standard, MEDLINE, Biobank, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Neurology, Pediatrics, Perinatology and Child Health, medicine, Diagnostic data, Medical physics, Neurology (clinical), business, 030217 neurology & neurosurgery, Genetics (clinical)
الوصف: • International CIDP registries were compared to assess infrastructure and collected clinical data, diagnostic data and biomaterials to enhance future research and improve standards of care in CIDP.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7db5408b7c5415bca8ab708876a9936fTest
https://doi.org/10.1016/j.nmd.2017.10.009Test -
6
المؤلفون: Mariëlle H.J. Pruppers, Ingemar S.J. Merkies, Michael P.T. Lunn, Nicolette C. Notermans, Peter van den Bergh, Patricia Blomkwist-Markens, David Cornblath, Shirley D'Sa, Catharina Faber, Stephan Goedee, Ken Gorson, Jean-Marc Léger, Richard Lewis, Michael Lunn, Lou Mazawey, Ingemar Merkies, Eduardo Nobile-Orazio, Nicolette Notermans, Luca Padua, Ludo van der Pol, Mariëlle Pruppers, Louis Querol, Andreas Steck, Hugh Willison
المصدر: Neuromuscular Disorders. 27:1065-1072
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, business.industry, Anti-MAG peripheral neuropathy, Outcome measures, Future assessment, Clinical neurology, 03 medical and health sciences, Monoclonal gammopathy, 030104 developmental biology, 0302 clinical medicine, Neurology, Family medicine, Pediatrics, Perinatology and Child Health, Demyelinating neuropathy, Medicine, Neurology (clinical), medicine.symptom, business, WALDENSTROMS MACROGLOBULINEMIA, 030217 neurology & neurosurgery, Genetics (clinical)
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c6577ac8e785f3a6a6ac3608be6f1c79Test
https://doi.org/10.1016/j.nmd.2017.08.001Test -
7
المؤلفون: Ivo N van Schaik, Orell Mielke, Arman Sabet, Koshy George, Leslie Roberts, Ross Carne, Stefan Blum, Robert Henderson, Philip Van Damme, Jelle Demeestere, Sandrine Larue, Catherine-Andree Pinard D'Amour, Vera Bril, Ari Breiner, Pavel Kunc, Martin Valis, Jana Sussova, Tomas Kalous, Radomir Talab, Michal Bednar, Toomas Toomsoo, Inna Rubanovits, Katrin Gross-Paju, Ulvi Sorro, Mika Saarela, Mari Auranen, Jean Pouget, Shahram Attarian, Gwendal Le Masson, Anne-Cécile Wielanek-Bachelet, Claude Desnuelle, Emilien Delmont, Pierre Clavelou, Dominique Aufauvre, Jens Schmidt, Jana Zschuentssch, Claudia Sommer, Daniela Kramer, Olaf Hoffmann, Carsten Goerlitz, Judith Haas, Marko Chatzopoulos, Min-Suk Yoon, Ralf Gold, Peter Berlit, Andrea Jaspert-Grehl, David Liebetanz, Anna Kutschenko, Martin Stangel, Corinna Trebst, Petra Baum, Florian Then Bergh, Juliane Klehmet, Andreas Meisel, Fabian Klostermann, Johanna Oechtering, Helmar Lehmann, Michael Schroeter, Tim Hagenacker, Daniel Mueller, Anne-Dorte Sperfeld, Florian Bethke, Hans-Peter Hartung, Vivian Drory, Avi Algom, David Yarnitsky, Beth Brianna Murinson, Antonio Di Muzio, Fausta Ciccocioppo, Sandro Sorbi, Sabrina Mata, Angelo Schenone, Marina Grandis, Giuseppe Lauria, Daniele Cazzato, Giovanni Antonini, Stefania Morino, Dario Cocito, Maurizio Zibetti, Takanori Yokota, Takuya Ohkubo, Takashi Kanda, Motoharu Kawai, Kenichi Kaida, Hiroyuki Onoue, Satoshi Kuwabara, Masahiro Mori, Masahiro Iijima, Ken Ohyama, Gen Sobue, Masayuki Baba, Masahiko Tomiyama, Kazutoshi Nishiyama, Tsugio Akutsu, Kazumasa Yokoyama, Kazuaki Kanai, Ivo N. van Schaik, Filip Eftimov, Nicolette. C. Notermans, Nora. A. Visser, Catharina Faber, Janneke. G.J. Hoeijmakers, Ingemar S.J. Merkies, Nan van Geloven, Konrad Rejdak, Urszula Chyrchel-Paszkiewicz, Carlos Casanovas Pons, María Antonia Alberti Aguiló, Josep Gamez, María Figueras, Celedonio Marquez Infante, Sonia Benitez Rivero, Michael Lunn, Jasper Morrow, David Gosal, Timothy Myles Lavin, Isaac Melamed, Alessandro Testori, Senda Ajroud-Driss, Daniela Menichella, Ericka Simpson, Eugene Chi-Ho Lai, Mazen Dimachkie, Richard J. Barohn, Said Beydoun, Harpreet Johl, Dale Lange, Alexander Shtilbans, Suraj Muley, Shafeeq Ladha, Miriam Freimer, John Kissel, Norman Latov, Russell Chin, Eroboghene Ubogu, Sandi Mumfrey, T. Hermanth P. Rao, Paul MacDonald, Khema Sharma, Ginna Gonzalez, Jeffrey Allen, David Walk, Lisa Hobson-Webb, Karissa Gable, Richard A. Lewis, David R. Cornblath, John-Phillip Lawo, Michaela Praus, Billie L. Durn
المساهمون: Hagenacker, Tim (Beitragende*r), Amsterdam Neuroscience - Neuroinfection & -inflammation, AII - Inflammatory diseases, Neurology
المصدر: Lancet neurology, 17(5), 393-394. Lancet Publishing Group
مصطلحات موضوعية: medicine.medical_specialty, biology, business.industry, Medizin, Immunoglobulins, Intravenous, Chronic inflammatory demyelinating polyneuropathy, Subcutaneous immunoglobulin, medicine.disease, Gastroenterology, Pharmacokinetics, Internal medicine, biology.protein, medicine, Administration, Intravenous, Neurology (clinical), Antibody, business
الوصف: We thank Ravi Uniyal and colleagues for their comments on our results from the PATH trial1 on subcutaneous immunoglobulin (SCIg) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). They express concern about the relapse rates in the treatment groups and hypothesise the cause being the pharmacokinetics of SCIg.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bbab476f42fdc4ef954363ef718221Test
http://hdl.handle.net/11567/941843Test -
8دورية أكاديمية
المصدر: Muscle & Nerve. Jul2003, Vol. 28 Issue 1, p93. 8p.
مصطلحات موضوعية: *GRIP strength, *MUSCLE strength, *POLYNEUROPATHIES, *WALKING, *MEDICAL research
مستخلص: The ability of a scale to detect clinical relevant changes over time, i.e., its responsiveness, may help clinicians to choose among valid and reliable measures. Therefore, we investigated the responsiveness' rank ordering (best to worse) of six selected valid and reliable scales, namely the Medical Research Council (MRC)-sumscore, sensory-sumscore, grip-strength (Vigorimeter), nine-hole peg, ten-meters walking, and a disability-sumscore, in immune-mediated polyneuropathies. Patients with newly diagnosed GuillainBarré syndrome (n = 7) or chronic inflammatory demyelinating polyneuropathy (n = 13) were examined over 52 weeks. Responsiveness of each scale was measured using different methods (effect-size, standardized response mean score, Wilcoxon matched-pairs signed-rank, and a newly devised Schmitz's distribution-free responsiveness score), and the obtained scores in each method were plotted against the follow-up period, thus allowing area-under-the-curve calculations (higher area-under-the-curve indicating better responsiveness). Also, longitudinal correlations were performed between the scales' values and patients' own clinical judgments (deteriorated, unchanged, improved) (higher correlation = better responsiveness). A consistent rank ordering was observed in each technique with the disability-sumscore, MRC-sumscore, and Vigorimeter being among the best responsive scales. Hence, the primary use of these measures is suggested in studies of immune-mediated polyneuropathies. Muscle Nerve 28: 93100, 2003 [ABSTRACT FROM AUTHOR]